Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Vincent P. Ippolito | MD & Executive Chairman | 422.9k | -- | 1959 |
| Dr. Howie McKibbon | Chief Executive Officer | 637.55k | -- | -- |
| Mr. Graeme Morissey | Chief Financial Officer | 63.39k | -- | -- |
| Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB | Executive Director | 246.52k | -- | 1973 |
| Dr. Jack Hoblitzell Ph.D. | Senior Vice President of Pharmaceutical Development | -- | -- | -- |
| Dr. Patricia S. Walker M.D., Ph.D. | Chief Medical Adviser | -- | -- | 1959 |
| Dr. Boris Meyerson Ph.D. | Chief Business Officer | -- | -- | -- |
| Mr. David Morgan | Head of Corporate Affairs | -- | -- | -- |
| Mr. Kevin Wojciechowski | Head of HCP Marketing & Sales Training | -- | -- | -- |
| Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin | Company Secretary | -- | -- | 1975 |
Botanix Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Corporate Governance
Upcoming Events
February 26, 2025 at 10:59 AM UTC - March 3, 2025 at 12:00 PM UTC
Botanix Pharmaceuticals Limited Earnings Date
Recent Events
Recent Events Information Not Available